亿胜生物科技(01061)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01061 亿胜生物科技

交易中 06-26 13:21:56

2.710

+0.010

+0.37%

最高2.750	最低2.680	成交量39.60万
今开2.700	昨收2.700	日振幅2.59%
总市值15.34亿	流通市值15.34亿	总股本5.66亿
成交额107.47万	换手率0.07%	流通股本5.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01061","market":"HK","secType":"STK","nameCN":"亿胜生物科技","latestPrice":2.71,"timestamp":1782451262487,"preClose":2.7,"halted":0,"volume":396000,"delay":0,"changeRate":0.0037037037037036245,"floatShares":566000000,"shares":566000000,"eps":0.561,"marketStatus":"交易中","change":0.01,"latestTime":"06-26 13:21:56","open":2.7,"high":2.75,"low":2.68,"amount":1074730,"amplitude":0.025926,"askPrice":2.75,"askSize":10000,"bidPrice":2.7,"bidSize":9000,"shortable":0,"etf":0,"ttmEps":0.561,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782461400000},"marketStatusCode":2,"adr":0,"listingDate":993571200000,"exchange":"SEHK","adjPreClose":2.7,"dividendRate":0.051661,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.823734,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01061","defaultTab":"news","newsList":[{"id":"1144513015","title":"亿胜生物科技：6月25日回购10万股，耗资约26.35万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144513015","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144513015?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:55","pubTimestamp":1782377743,"startTime":"0","endTime":"0","summary":"亿胜生物科技（股票代码：01061）于2026年6月25日公告，基于回购授权在香港联交所场内回购合计10万股普通股，占该次事件前已发行股本（不包括库藏股）约0.01765%。每股回购价介乎港币2.63元至2.64元，合计支付约26.35万港元。回购完成后，公司已发行股本（不包括库藏股）变更为5.66333亿股，库藏股数增至67.3万股。\n公司此前于2026年5月26日通过回购授权，总可回购股份数为5670.06万股。截至目前，公司已在交易所累积回购67.3万股，占授权通过日已发行股本的约0.11869%。公告同时确认已遵守相关上市规则与法例程序。\n本公告由公司董事方海洲签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿胜生物科技：6月25日回购10万股，耗资约26.35万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196160113","title":"亿胜生物科技回购247,000股股份，总金额约64.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196160113","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196160113?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:06","pubTimestamp":1782292014,"startTime":"0","endTime":"0","summary":"亿胜生物科技有限公司于2026年6月24日发布翌日披露报表，宣布在当日回购普通股247,000股，占该公告披露前已发行股份总数约0.04359%。本次回购价格区间为每股2.61港元至2.64港元，累计耗资约64.87万港元。根据此前于2026年5月26日通过的购回授权，亿胜生物科技可回购股份的总数为56,700,600股。公告同时确认，公司已遵守香港联合交易所有限公司证券上市规则及相关法律规章。本公告由公司董事方海洲签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿胜生物科技回购247,000股股份，总金额约64.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645896528","title":"亿胜生物科技(01061)6月24日耗资约64.87万港元回购24.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645896528","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645896528?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:05","pubTimestamp":1782291953,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)公布，2026年6月24日耗资约64.87万港元回购24.7万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154659235","title":"亿胜生物科技回购12万股股份，涉资约31.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154659235","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154659235?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:55","pubTimestamp":1782204955,"startTime":"0","endTime":"0","summary":"6月23日，亿胜生物科技有限公司（股票代码：01061）发布公告，披露于当日于香港联交所回购合计120,000股普通股，约占回购前已发行股本的0.02117%。回购价格区间为每股2.63港元至2.65港元，总支付金额为317,280港元（约合31.73万港元）。\n本次回购完成后，公司已发行股本为566,680,000股，库藏股数量增至326,000股。根据公告，股东大会于2026年5月26日通过了回购授权，授权回购总额为56,700,600股。截至目前，公司已累计回购326,000股。公司确认上述回购行为符合香港联合交易所有限公司证券上市规则及其他相关法律法规。\n本公告由董事方海洲签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿胜生物科技回购12万股股份，涉资约31.73万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645848568","title":"亿胜生物科技(01061)6月23日斥资31.73万港元回购12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645848568","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645848568?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:55","pubTimestamp":1782204942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，于2026年6月23日，该公司斥资31.73万港元回购12万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155458703","title":"亿胜生物科技：6月22日回购7.1万股，耗资约18.64万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155458703","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155458703?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:56","pubTimestamp":1782118587,"startTime":"0","endTime":"0","summary":"亿胜生物科技于6月22日发布公告，披露其在香港联交所场内回购股份。公司当日共回购股份71,000股，占前一交易日已发行股本约0.01252%，回购价格介乎每股2.62港元至2.64港元，总金额为186,440港元。公司于2026年5月26日曾通过购回授权，可回购合计56,700,600股；目前在香港联交所或其他证券交易所已累计回购206,000股，占授权决议通过当日已发行股本的约0.03633%。公司同时确认，已遵守香港联交所《证券上市规则》及相关法律法规。公告由董事方海洲签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿胜生物科技：6月22日回购7.1万股，耗资约18.64万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040412","title":"亿胜生物科技(01061)6月22日斥资18.64万港元回购7.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645040412?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:52","pubTimestamp":1782118339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，于2026年6月22日该公司斥资18.64万港元回购7.1万股，回购价格为每股2.62-2.64港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199639838","title":"亿胜生物科技：6月18日回购13.5万股，耗资约35.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199639838","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199639838?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:41","pubTimestamp":1781779312,"startTime":"0","endTime":"0","summary":"亿胜生物科技有限公司于2026年6月18日公告回购普通股股份。根据披露信息，本次于香港联交所场内回购股份共计135,000股，占回购前公司已发行股本约0.02381%。回购价格区间每股2.63港元至2.65港元，合计支付约35.66万港元。公司回购授权决议于2026年5月26日通过，本次授权可购回最高总数为56,700,600股；截至目前，已于香港联交所回购135,000股，占授权通过当日公司已发行股本约0.02381%。上述公告由董事方海洲签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿胜生物科技：6月18日回购13.5万股，耗资约35.66万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644075167","title":"亿胜生物科技(01061)6月18日斥资约35.66万港元回购13.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644075167","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644075167?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:41","pubTimestamp":1781779275,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，于2026年6月18日该公司斥资约35.66万港元回购13.5万股，回购价格为每股2.63至2.65港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156266712","title":"复宏汉霖宣布HLX04-O治疗湿性年龄相关性黄斑变性三期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1156266712","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156266712?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:47","pubTimestamp":1781606876,"startTime":"0","endTime":"0","summary":"6月16日，上海复宏汉霖生物技术股份有限公司（2696.HK）宣布，其用于治疗湿性年龄相关性黄斑变性（wAMD）的药物HLX04-O，在三期临床研究中已达到预设的主要终点。\n该研究的成功标志着公司在眼科生物类似药领域取得了重要进展。湿性年龄相关性黄斑变性是导致老年人视力丧失的主要原因之一，HLX04-O作为一款创新候选药物，其临床数据备受市场关注。\n公司后续将根据相关法规要求，推进该产品的上市申请工作。此次研究结果的公布，预计将对复宏汉霖的产品管线价值及未来发展产生积极影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","HK0000320223.HKD","01061","02696","HK0000306685.HKD","00656","BK1230","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149733911","title":"亿胜生物科技5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1149733911","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149733911?lang=zh_cn&edition=full","pubTime":"2026-06-02 12:05","pubTimestamp":1780373152,"startTime":"0","endTime":"0","summary":"亿胜生物科技于2026年6月2日发布截至2026年5月31日的证券变动月报表。报告期内，公司已发行股份数量为567,006,000股，库存股份数量为0股，合计总数继续保持在567,006,000股，未出现新增发行、回购、注销或库藏股变动。关于股份期权，公司根据股东大会通过的购股权计划，持有57,064,900份尚未行使的期权，报告期内并未因该计划新增发行股份或转让库存股份。报告期内不存在可换股票据或其他发行协议变动。截至5月末，公司股本数量保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121003294","title":"亿胜生物科技4月股份变动月报表维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1121003294","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121003294?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:56","pubTimestamp":1777885007,"startTime":"0","endTime":"0","summary":"亿胜生物科技（股票代码：01061）于2026年5月4日发布截至2026年4月30日的股份变动月报表。公告显示，公司注册股本为10亿股普通股，每股面值为0.1港元，注册股本总额1亿港元。报告期末，公司已发行及流通在外股份总数为567,006,000股，与上月底保持一致，未发生新增发行、购回或注销股份情况。\n与此同时，公司2023年6月9日通过的股份期权计划在本月末仍可发行或转让股份数量为57,064,900股，报告期内并无实际行使或新增发行。公司确认已符合香港联交所规定的最低公众持股量要求。\n本次月报由董事方海洲签署。公告显示，截至4月底，公司总体股本结构保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180387139","title":"亿胜生物科技3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1180387139","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180387139?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:38","pubTimestamp":1775032714,"startTime":"0","endTime":"0","summary":"亿胜生物科技有限公司于2026年4月1日披露了截至2026年3月31日的股份变动月报表。报告显示，公司本月无新增发行、购回或注销股份，整体股本结构保持不变。根据公告，截至3月31日，公司法定注册股本仍为1,000,000,000股，面值每股0.1港元，对应注册股本总额为1亿港元。公司确认继续符合香港联交所规定的公众持股量要求。本次月报由公司董事方海洲签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147587552","title":"亿胜生物科技（01061）2025年收入达18.14亿港元　三大板块协同带动盈利增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1147587552","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147587552?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:46","pubTimestamp":1774946778,"startTime":"0","endTime":"0","summary":"亿胜生物科技公布截至2025年12月31日止年度业绩。报告期内，公司实现营业额约18.14亿港元，较2024年的16.70亿港元增长8.6%。销售成本约1.96亿港元，带动毛利增至16.17亿港元，毛利率保持在逾八成水平。年内溢利为3.18亿港元，同比上升3.5%，净利率约17.5%。分业务来看，眼科、外科及医疗保健及陪伴服务三大板块均对收入增长有所贡献。报告期内，公司持续加大科研投入，研发支出占收入比例超过9%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180285535","title":"亿胜生物科技授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1180285535","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180285535?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:41","pubTimestamp":1774946517,"startTime":"0","endTime":"0","summary":"亿胜生物科技有限公司（股票代码：01061）公布将向股东寻求授权，于2026年5月26日召开股东周年大会，审议授予董事一般性购回股份授权，最高可达公司已发行股本的10%。根据公告，公司目前已发行股份总数约为567,006,000股，若获通过，购回规模最高可达56,700,600股。\n公告显示，购回所需资金将来自公司可合法动用的资金来源，符合香港上市规则及开曼群岛相关法律规定。董事会表示，将在市况允许且有利于公司及股东整体利益时行使购回授权，以优化资本结构并提升股东回报。\n公司提醒股东，相关决议将于2026年5月26日的股东周年大会上进行表决，届时需股东审议并表决通过方可正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622887980","title":"国元国际：亿胜生物科技(01061)价值低估 建议积极关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622887980?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:17","pubTimestamp":1774495040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，亿胜生物科技(01061)2025年实现营业额18.14亿港元，较2024年增加8.6%，主因眼科与外科板块持续发力。溢利较2024年增加3.5%至3.18亿港元。贝复舒已通过新加坡特别采用程式成功引入新加坡国家眼科中心，此里程碑标志产品首次进入中国以外地区，为未来在东南亚及全球市场推出奠定基础。该行指，公司原有业务稳健增长，能提供较好的现金流，新产品贝伐珠单抗三期临床试验达到主要临床终点，该产品的国内以及海外市场空间广阔，随着创新药未来商业化顺利推进，将推动公司业绩上升。目前静态PE仅为6.5倍，价值低估，建议积极关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770969","title":"亿胜生物科技(01061)发布年度业绩，年内溢利3.18亿港元 同比增加3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770969","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621770969?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:16","pubTimestamp":1774264582,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布截至2025年12月31日止年度全年业绩，该公司取得营业额18.14亿港元，同比增加8.62%;年内溢利3.18亿港元，同比增加3.54%;每股盈利56.10港仙;拟派末期股息每股0.07港元。公告称，截至2025年12月31日止年度，眼科为集团营业额贡献约8.35亿港元，较2024年增加8.2%。截至2025年12月31日止年度，外科录得总营业额约8.96亿港元，较2024年增加1.8%。截至2025年12月31日止年度，医疗保健及伙伴服务录得总营业额约8290万港元，较2024年大幅增加350%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101672155","title":"亿胜生物科技2025年收益与盈利均攀升，研发投入占比提升至9.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101672155","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101672155?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:15","pubTimestamp":1774264509,"startTime":"0","endTime":"0","summary":"亿胜生物科技于二零一五年度实现收益约1,813,807,000港元，较二零一四年增加8.6%，毛利约1,617,886,030港元，毛利率为89.2%。同期年内溢利约318,091,163港元，同比增长3.5%，净利率为17.5%。分部业务中，眼科分部收益约835,031,993港元，占整体收益46.0%；外科分部收益约895,903,688港元，占49.4%；医疗保健及赋能服务分部收益约82,871,576港元，占4.6%。整体而言，集团收益和盈利持续增长，毛利率表现稳定，流动资金状况良好，且研发投入在收入中的占比有所提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708777","title":"亿胜生物科技(01061)将于6月12日派发末期股息每股0.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708777","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621708777?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:12","pubTimestamp":1774264372,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，将于2026年6月12日派发截至2025年12月31日止年度末期股息每股0.07港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01061","BK1161","BK4588","VIG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141256944","title":"亿胜生物科技将于2026年6月12日派发末期股息每股0.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141256944","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141256944?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:11","pubTimestamp":1774264318,"startTime":"0","endTime":"0","summary":"亿胜生物科技(01061)发布公告显示，公司已宣布派发截至2025年12月31日止年度末期股息，每股为0.07港元。该股息尚待股东于2026年5月26日批准。\n根据公告，除净日为2026年5月28日，为符合获得股息分派而递交股份过户文件的最后时限为2026年5月29日16时30分。公司将于2026年6月1日至6月3日暂停办理股份过户登记手续，记录日期为2026年6月3日。股息派发日定于2026年6月12日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01061"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.essexbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.234},{"period":"6month","weight":-0.2893},{"period":"1year","weight":-0.4138},{"period":"ytd","weight":-0.2667}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0985},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1062},{"period":"1year","weight":-0.0571},{"period":"ytd","weight":-0.0996}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亿胜生物科技有限公司是一家主要从事生产及销售治疗体表创伤和眼部损伤生物药品的投资控股公司。该公司通过三个业务分部进行运营。外科分部主要从事开发、制造及销售贝复济液体制剂、贝复济冻干粉及贝复新凝胶以及其他产品。眼科分部从事开发、制造与销售贝复舒滴眼液、贝复舒眼用凝胶及贝复舒单剂量滴眼液以及其他产品。提供服务分部主要从事提供医疗科技电子平台相关医疗服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.733333,"avgChangeRate":0.036282},{"month":2,"riseRate":0.6,"avgChangeRate":0.051619},{"month":3,"riseRate":0.533333,"avgChangeRate":0.042805},{"month":4,"riseRate":0.466667,"avgChangeRate":0.031977},{"month":5,"riseRate":0.4,"avgChangeRate":-0.012005},{"month":6,"riseRate":0.4,"avgChangeRate":0.023156},{"month":7,"riseRate":0.357143,"avgChangeRate":-0.026551},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.002168},{"month":9,"riseRate":0.533333,"avgChangeRate":0.03471},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013996},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008914},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.018984}],"exchange":"SEHK","name":"亿胜生物科技","nameEN":"ESSEX BIO-TECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿胜生物科技(01061)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿胜生物科技(01061)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿胜生物科技,01061,亿胜生物科技股票,亿胜生物科技股票老虎,亿胜生物科技股票老虎国际,亿胜生物科技行情,亿胜生物科技股票行情,亿胜生物科技股价,亿胜生物科技股市,亿胜生物科技股票价格,亿胜生物科技股票交易,亿胜生物科技股票购买,亿胜生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿胜生物科技(01061)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿胜生物科技(01061)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}